首页 > 最新文献

Personalized medicine最新文献

英文 中文
Role of precision nutrition in improving military performance. 精确营养在提高军事性能中的作用。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-16 DOI: 10.2217/pme-2021-0120
Coimbatore Subburaj Thiruvenkataswamy, M. Appukutty, K. S. Vimaleswaran
Graphical abstract [Formula: see text] Role of precision nutrition in improving military performance.
图形摘要[公式:见正文]精确营养在提高军事性能中的作用。
{"title":"Role of precision nutrition in improving military performance.","authors":"Coimbatore Subburaj Thiruvenkataswamy, M. Appukutty, K. S. Vimaleswaran","doi":"10.2217/pme-2021-0120","DOIUrl":"https://doi.org/10.2217/pme-2021-0120","url":null,"abstract":"Graphical abstract [Formula: see text] Role of precision nutrition in improving military performance.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49388425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
State-of-the-art knowledge on the regulation of advanced therapy medicinal products. 先进治疗药品监管方面的最新知识。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-16 DOI: 10.2217/pme-2021-0111
Patcharaphun Kidpun, Warit Ruanglertboon, R. Chalongsuk
Advanced therapy medicinal products (ATMPs) constitute therapeutic agents based on obtained cells, tissues or genes representing a novel treatment opportunity in medicine. In addition, ATMPs are administered into the cells or tissues of humans from the patient's own cells, donors, or genetically modified cells. Recently, the field of developing ATMPs has become a point of attention due to the clinical efficacy expected in defeating incurable diseases such as cancers and neurodegenerative disorders. Currently, there are two modes regarding the distribution of ATMPs. First, ATMPs that might be legally authorized for marketing. Second, the patients are able to access unapproved ATMPs through the hospital exemption (HE) or clinical practice program or through the compassionate use and expanded access program. The aim of this review is to discuss state-of-the-art knowledge on the regulation of ATMPs and provide regulatory recommendations.
高级治疗药物(ATMP)是基于获得的细胞、组织或基因的治疗剂,代表了医学中的新治疗机会。此外,ATMP是从患者自身的细胞、供体或转基因细胞给药到人类的细胞或组织中的。最近,由于在战胜癌症和神经退行性疾病等不治之症方面的临床疗效,开发ATMP的领域已成为人们关注的焦点。目前,ATM的分配有两种模式。首先,可能被合法授权进行营销的ATM。其次,患者可以通过医院豁免(HE)或临床实践计划,或通过同情使用和扩大访问计划,访问未经批准的ATM。本次审查的目的是讨论ATM监管的最新知识,并提供监管建议。
{"title":"State-of-the-art knowledge on the regulation of advanced therapy medicinal products.","authors":"Patcharaphun Kidpun, Warit Ruanglertboon, R. Chalongsuk","doi":"10.2217/pme-2021-0111","DOIUrl":"https://doi.org/10.2217/pme-2021-0111","url":null,"abstract":"Advanced therapy medicinal products (ATMPs) constitute therapeutic agents based on obtained cells, tissues or genes representing a novel treatment opportunity in medicine. In addition, ATMPs are administered into the cells or tissues of humans from the patient's own cells, donors, or genetically modified cells. Recently, the field of developing ATMPs has become a point of attention due to the clinical efficacy expected in defeating incurable diseases such as cancers and neurodegenerative disorders. Currently, there are two modes regarding the distribution of ATMPs. First, ATMPs that might be legally authorized for marketing. Second, the patients are able to access unapproved ATMPs through the hospital exemption (HE) or clinical practice program or through the compassionate use and expanded access program. The aim of this review is to discuss state-of-the-art knowledge on the regulation of ATMPs and provide regulatory recommendations.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45924052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
How can we address the uncertainties regarding the potential clinical utility of polygenic score-based tests? 我们如何解决基于多基因评分的测试潜在临床效用的不确定性?
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-15 DOI: 10.2217/pme-2021-0148
S. Moorthie, A. Hall, Chantal Babb de Villiers, Joanna Janus, Tanya Brigden, Laura Blackburn, M. Kroese
As common low penetrance variants associated with diseases are uncovered, attempts continue to be made to harness this knowledge for improving healthcare. Polygenic scores have been developed as the mechanism by which knowledge of common variants can be used to investigate genetic contributions to disease risk. They serve as a biomarker to provide an estimate of the genetic liability for a particular disease. Discussion continues as to whether polygenic scores are a useful biomarker and their readiness for incorporation into clinical and public health practice. In this paper, we investigate the key challenges that need to be addressed, in the description and assessment of the clinical utility of polygenic score-based tests for use in clinical and public health practice.
随着与疾病相关的常见低外显率变异被发现,人们继续试图利用这一知识来改善医疗保健。多基因评分已经发展成为一种机制,通过这种机制,常见变异的知识可以用来研究遗传对疾病风险的影响。它们作为一种生物标志物,提供对特定疾病的遗传倾向性的估计。关于多基因评分是否是一种有用的生物标志物,以及它们是否适合用于临床和公共卫生实践的讨论仍在继续。在本文中,我们调查了在临床和公共卫生实践中使用的多基因评分测试的临床效用的描述和评估中需要解决的关键挑战。
{"title":"How can we address the uncertainties regarding the potential clinical utility of polygenic score-based tests?","authors":"S. Moorthie, A. Hall, Chantal Babb de Villiers, Joanna Janus, Tanya Brigden, Laura Blackburn, M. Kroese","doi":"10.2217/pme-2021-0148","DOIUrl":"https://doi.org/10.2217/pme-2021-0148","url":null,"abstract":"As common low penetrance variants associated with diseases are uncovered, attempts continue to be made to harness this knowledge for improving healthcare. Polygenic scores have been developed as the mechanism by which knowledge of common variants can be used to investigate genetic contributions to disease risk. They serve as a biomarker to provide an estimate of the genetic liability for a particular disease. Discussion continues as to whether polygenic scores are a useful biomarker and their readiness for incorporation into clinical and public health practice. In this paper, we investigate the key challenges that need to be addressed, in the description and assessment of the clinical utility of polygenic score-based tests for use in clinical and public health practice.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47165117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Exploring the usefulness of plasma level determination and pharmacogenetics for patients treated with clozapine. 探讨血浆水平测定和药物遗传学对氯氮平治疗患者的有用性。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-09 DOI: 10.2217/pme-2021-0029
Estela Sangüesa, Christine Cirujeda, Julia Concha, P. Padilla, C. García, M. Ribate
Aims: The aims of the present study were to assess the variance of plasma clozapine (CLZ) levels and to identify the influence of sociodemographic and pharmacogenetic factors on it and to introduce these tools in a clinical setting. Patients & methods: CLZ concentration was measured and genetic variants of CLZ pharmacokinetic and pharmacodynamic factors were assessed in 23 patients with psychotic disorders. Results: A significant association between mean concentration/dose ratio (C/D) and smoking status, age and weight were found. There was a significant difference in mean plasma CLZ levels and gender. The rs762551 AA genotype in smokers had a significantly lower C/D. Conclusion: In addition to classical factors, monitoring of plasma concentrations together with pharmacogenetics led to greater individualization of treatment.
目的:本研究的目的是评估血浆氯氮平(CLZ)水平的变化,确定社会人口统计学和药物遗传学因素对其的影响,并在临床环境中引入这些工具。患者和方法:测定23例精神病患者的CLZ浓度,并评估CLZ药代动力学和药效学因素的遗传变异。结果:平均浓度/剂量比(C/D)与吸烟状况、年龄和体重之间存在显著相关性。平均血浆CLZ水平和性别存在显著差异。吸烟者rs762551 AA基因型的C/D显著降低。结论:除经典因素外,监测血浆浓度和药物遗传学可提高治疗的个体化程度。
{"title":"Exploring the usefulness of plasma level determination and pharmacogenetics for patients treated with clozapine.","authors":"Estela Sangüesa, Christine Cirujeda, Julia Concha, P. Padilla, C. García, M. Ribate","doi":"10.2217/pme-2021-0029","DOIUrl":"https://doi.org/10.2217/pme-2021-0029","url":null,"abstract":"Aims: The aims of the present study were to assess the variance of plasma clozapine (CLZ) levels and to identify the influence of sociodemographic and pharmacogenetic factors on it and to introduce these tools in a clinical setting. Patients & methods: CLZ concentration was measured and genetic variants of CLZ pharmacokinetic and pharmacodynamic factors were assessed in 23 patients with psychotic disorders. Results: A significant association between mean concentration/dose ratio (C/D) and smoking status, age and weight were found. There was a significant difference in mean plasma CLZ levels and gender. The rs762551 AA genotype in smokers had a significantly lower C/D. Conclusion: In addition to classical factors, monitoring of plasma concentrations together with pharmacogenetics led to greater individualization of treatment.","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"1 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2022-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41651554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Interindividual variability in diabetic patients' response to opium poppy: an overview of impressive factors. 糖尿病患者对罂粟反应的个体差异:令人印象深刻的因素概述。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-01 DOI: 10.2217/pme-2021-0107
Fatemeh Hendijani, Fatemeh Sadat Hosseini

Diabetic patients always seek alternative treatments to lower their blood glucose level efficiently, because antidiabetic drugs produce adverse effects and many patients experience reduced response after a treatment period. Opium poppy (Papaver somniferum) is frequently consumed by diabetic patients for reduction of blood glucose level. Scientific studies found controversial results in the investigation of the blood glucose-lowering effects of opium poppy. In this regard, we explored the antidiabetic effect of opium poppy more closely. The antidiabetic or antihyperglycemic effect of P. somniferum alkaloids were reviewed. Next, opioid receptors and their role in diabetes were explored. In the final part origins of interindividual variabilities in opioid receptors and metabolizing enzymes' functions including genetic and epigenetic factors were reviewed.

糖尿病患者总是寻求替代治疗来有效降低血糖水平,因为降糖药物会产生不良反应,许多患者在治疗一段时间后反应降低。罂粟(Papaver somniferum)常被糖尿病患者食用以降低血糖水平。科学研究在对罂粟降血糖效果的调查中发现了有争议的结果。在这方面,我们更密切地探讨了罂粟的抗糖尿病作用。本文综述了菟菟子生物碱的降糖、降血糖作用。接下来,探讨阿片受体及其在糖尿病中的作用。最后,综述了阿片受体和代谢酶功能的个体间变异的起源,包括遗传和表观遗传因素。
{"title":"Interindividual variability in diabetic patients' response to opium poppy: an overview of impressive factors.","authors":"Fatemeh Hendijani,&nbsp;Fatemeh Sadat Hosseini","doi":"10.2217/pme-2021-0107","DOIUrl":"https://doi.org/10.2217/pme-2021-0107","url":null,"abstract":"<p><p>Diabetic patients always seek alternative treatments to lower their blood glucose level efficiently, because antidiabetic drugs produce adverse effects and many patients experience reduced response after a treatment period. Opium poppy (<i>Papaver somniferum</i>) is frequently consumed by diabetic patients for reduction of blood glucose level. Scientific studies found controversial results in the investigation of the blood glucose-lowering effects of opium poppy. In this regard, we explored the antidiabetic effect of opium poppy more closely. The antidiabetic or antihyperglycemic effect of <i>P. somniferum</i> alkaloids were reviewed. Next, opioid receptors and their role in diabetes were explored. In the final part origins of interindividual variabilities in opioid receptors and metabolizing enzymes' functions including genetic and epigenetic factors were reviewed.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 2","pages":"155-163"},"PeriodicalIF":2.3,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9547356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BRAF: a biomarker not to be missed in glioblastoma. BRAF:胶质母细胞瘤不可错过的生物标志物。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-01 Epub Date: 2022-01-21 DOI: 10.2217/pme-2021-0118
Georges Ayoub, Elie Chalhoub, Hampig Raphael Kourie
{"title":"BRAF: a biomarker not to be missed in glioblastoma.","authors":"Georges Ayoub,&nbsp;Elie Chalhoub,&nbsp;Hampig Raphael Kourie","doi":"10.2217/pme-2021-0118","DOIUrl":"https://doi.org/10.2217/pme-2021-0118","url":null,"abstract":"","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":"79-82"},"PeriodicalIF":2.3,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39845589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum. 有待纠正。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-01 Epub Date: 2022-02-24 DOI: 10.2217/pme-2021-0061c1
{"title":"Corrigendum.","authors":"","doi":"10.2217/pme-2021-0061c1","DOIUrl":"https://doi.org/10.2217/pme-2021-0061c1","url":null,"abstract":"","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":"165"},"PeriodicalIF":2.3,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39949548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient views on genetics and functional imaging for precision medicine: a willingness-to-pay analysis. 患者对精准医学遗传学和功能成像的看法:付费意愿分析。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-01 Epub Date: 2022-01-05 DOI: 10.2217/pme-2021-0067
Kerstin Clasen, Cihan Gani, Christopher Schroeder, Olaf Riess, Daniel Zips, Oliver Schöffski, Stephan Clasen

Purpose: Willingness-to-pay (WTP) analyses can support allocation processes considering the patients preferences in personalized medicine. However, genetic testing especially might imply ethical concerns that have to be considered. Methods: A WTP questionnaire was designed to compare preferences for imaging and genetic testing in cancer patients and to evaluate potential ethical concerns. Results: Comparing the options of imaging and genetics showed comparable WTP values. Ethical concerns about genetic testing seemed to be minor. Treatment success was the top priority irrespective of the diagnostic modality. In general, the majority of patients considered personalized medicine to be beneficial. Conclusion: Most patients valued personalized approaches and rated the benefits of precision medicine of overriding importance irrespective of modality or ethical concerns.

目的:支付意愿(WTP)分析可以为考虑患者个性化医疗偏好的分配过程提供支持。然而,基因检测尤其可能意味着必须考虑的伦理问题。方法:设计一份WTP问卷,比较癌症患者对影像学和基因检测的偏好,并评估潜在的伦理问题。结果:比较影像学和遗传学的选择显示相当的WTP值。对基因检测的伦理担忧似乎是次要的。无论诊断方式如何,治疗成功都是重中之重。一般来说,大多数患者认为个性化医疗是有益的。结论:大多数患者重视个性化治疗方法,并将精准医疗的益处评价为压倒一切的重要性,而不考虑治疗方式或伦理问题。
{"title":"Patient views on genetics and functional imaging for precision medicine: a willingness-to-pay analysis.","authors":"Kerstin Clasen,&nbsp;Cihan Gani,&nbsp;Christopher Schroeder,&nbsp;Olaf Riess,&nbsp;Daniel Zips,&nbsp;Oliver Schöffski,&nbsp;Stephan Clasen","doi":"10.2217/pme-2021-0067","DOIUrl":"https://doi.org/10.2217/pme-2021-0067","url":null,"abstract":"<p><p><b>Purpose:</b> Willingness-to-pay (WTP) analyses can support allocation processes considering the patients preferences in personalized medicine. However, genetic testing especially might imply ethical concerns that have to be considered. <b>Methods:</b> A WTP questionnaire was designed to compare preferences for imaging and genetic testing in cancer patients and to evaluate potential ethical concerns. <b>Results:</b> Comparing the options of imaging and genetics showed comparable WTP values. Ethical concerns about genetic testing seemed to be minor. Treatment success was the top priority irrespective of the diagnostic modality. In general, the majority of patients considered personalized medicine to be beneficial. <b>Conclusion:</b> Most patients valued personalized approaches and rated the benefits of precision medicine of overriding importance irrespective of modality or ethical concerns.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":"103-112"},"PeriodicalIF":2.3,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39785681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Personalized approach in arrhythmology by genetic-based data: a case report. 基于遗传学数据的心律失常个性化方法:1例报告。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-01 Epub Date: 2022-01-21 DOI: 10.2217/pme-2021-0090
Anastasia Victorovna Blokhina, Alexandra Igorevna Ershova, Elena Vitalievna Zyatenkova, Alexey Nikolaevich Meshkov, Anna Vitalievna Kiseleva, Marina Vyacheslavovna Klimushina, Evgeniia Andreevna Sotnikova, Olga Petrovna Skirko, Anastasia Alexandrovna Zharikova, Yurii Valerievich Doludin, Maria Sergeevna Kharlap, Oxana Mikhailovna Drapkina

The results of molecular genetic testing may affect recommended treatment or therapeutic decisions and risk assessment, may help with identification of family members at risk. Here, we report a case of a young patient with a paradoxical combination of two inherited arrhythmic syndromes and demonstrate the role of genetic testing as one of the basis of personalized approach in diagnosis, treatment and prevention complications of inherited channelopathies complications. Integration of genetic testing results into clinical practice is a successful example of the concept of personalized medicine.

分子基因检测的结果可能会影响推荐的治疗方案或治疗决定和风险评估,可能有助于识别有风险的家庭成员。在这里,我们报告了一例年轻患者的两种遗传性心律失常综合征的矛盾组合,并证明了基因检测作为诊断、治疗和预防遗传性通道病变并发症的个性化方法的基础之一的作用。将基因检测结果纳入临床实践是个体化医疗概念的成功范例。
{"title":"Personalized approach in arrhythmology by genetic-based data: a case report.","authors":"Anastasia Victorovna Blokhina,&nbsp;Alexandra Igorevna Ershova,&nbsp;Elena Vitalievna Zyatenkova,&nbsp;Alexey Nikolaevich Meshkov,&nbsp;Anna Vitalievna Kiseleva,&nbsp;Marina Vyacheslavovna Klimushina,&nbsp;Evgeniia Andreevna Sotnikova,&nbsp;Olga Petrovna Skirko,&nbsp;Anastasia Alexandrovna Zharikova,&nbsp;Yurii Valerievich Doludin,&nbsp;Maria Sergeevna Kharlap,&nbsp;Oxana Mikhailovna Drapkina","doi":"10.2217/pme-2021-0090","DOIUrl":"https://doi.org/10.2217/pme-2021-0090","url":null,"abstract":"<p><p>The results of molecular genetic testing may affect recommended treatment or therapeutic decisions and risk assessment, may help with identification of family members at risk. Here, we report a case of a young patient with a paradoxical combination of two inherited arrhythmic syndromes and demonstrate the role of genetic testing as one of the basis of personalized approach in diagnosis, treatment and prevention complications of inherited channelopathies complications. Integration of genetic testing results into clinical practice is a successful example of the concept of personalized medicine.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":"83-91"},"PeriodicalIF":2.3,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39846040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The interplay between pharmacogenetics, concomitant drugs and blood levels of amitriptyline and its main metabolites. 药物遗传学、伴随药物与阿米替林及其主要代谢物血药水平之间的相互作用。
IF 2.3 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2022-03-01 Epub Date: 2022-02-04 DOI: 10.2217/pme-2021-0022
Luana Mifsud Buhagiar, Marilyn Casha, Anton Grech, Anthony Serracino Inglott, Godfrey LaFerla

Background: The research considers the impact of genotype-inferred variability on blood levels of amitriptyline and its main metabolites, as may be moderated by phenocopying. Patients & methods:CYP2D6 and CYP2C19 genotypes, and serum concentrations of amitriptyline, nortriptyline and hydroxymetabolites, were determined in 33 outpatients. Co-medications were reviewed to identify CYP inhibition risk. Results: CYP2C19 metabolizer status explained interpatient variation in nortriptyline to amitriptyline concentration ratios. The hydroxymetabolite to parent ratios increased with higher CYP2D6 activity scores and lower CYP2D6 inhibition risk. In patients at high CYP2D6 inhibition risk, the amitriptyline + nortriptyline concentration was, on average, 52% above the higher end of expected ranges. Conclusion: Practical construal of pharmacogenetics and drug interactions tantamount to aberrant metabolism can facilitate patient-tailored use of the established drug.

背景:该研究考虑了基因型推断的变异对阿米替林及其主要代谢物血液水平的影响,这可能通过表型复制来调节。患者与方法:测定33例门诊患者的CYP2D6、CYP2C19基因型及血清阿米替林、去甲替林、羟代谢物浓度。回顾联合用药以确定CYP抑制风险。结果:CYP2C19代谢状态解释了去甲替林与阿米替林浓度比的患者间差异。CYP2D6活性评分越高,CYP2D6抑制风险越低,羟基代谢物与亲本比值越高。在CYP2D6抑制风险高的患者中,阿米替林+去甲替林浓度平均比预期范围的上限高出52%。结论:对药物遗传学和药物相互作用等同于异常代谢的实际解释可以促进患者量身定制既定药物的使用。
{"title":"The interplay between pharmacogenetics, concomitant drugs and blood levels of amitriptyline and its main metabolites.","authors":"Luana Mifsud Buhagiar,&nbsp;Marilyn Casha,&nbsp;Anton Grech,&nbsp;Anthony Serracino Inglott,&nbsp;Godfrey LaFerla","doi":"10.2217/pme-2021-0022","DOIUrl":"https://doi.org/10.2217/pme-2021-0022","url":null,"abstract":"<p><p><b>Background:</b> The research considers the impact of genotype-inferred variability on blood levels of amitriptyline and its main metabolites, as may be moderated by phenocopying. <b>Patients & methods:</b><i>CYP2D6</i> and <i>CYP2C19</i> genotypes, and serum concentrations of amitriptyline, nortriptyline and hydroxymetabolites, were determined in 33 outpatients. Co-medications were reviewed to identify CYP inhibition risk. <b>Results:</b> CYP2C19 metabolizer status explained interpatient variation in nortriptyline to amitriptyline concentration ratios. The hydroxymetabolite to parent ratios increased with higher CYP2D6 activity scores and lower CYP2D6 inhibition risk. In patients at high CYP2D6 inhibition risk, the amitriptyline + nortriptyline concentration was, on average, 52% above the higher end of expected ranges. <b>Conclusion:</b> Practical construal of pharmacogenetics and drug interactions tantamount to aberrant metabolism can facilitate patient-tailored use of the established drug.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":" ","pages":"113-123"},"PeriodicalIF":2.3,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39889273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Personalized medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1